Four executive orders have been issued since March 28, 2017.
The March 29 order establishes a Commission on Combating Drug Addition and the Opioid Crisis. On the surface it appears to be a routine order, but underlying is the probable intent to establish yet another “citizen review” group appointed by the president to determine the “effectiveness” of the various Federal expenditures on drug prevention and opioid abuse. While I am quite sure the opioid crisis is real, I am skeptical about this as any kind of solution.
The other three orders were issued March 31. One is on the topic of trade deficits, a second is a change to the order of succession in the Justice Department, and the third is related to trade and customs laws.
According to this administration, the United States is not getting proper trade benefits from current trading partners. Thus the executive order to require a report on trade deficits to be prepared by the Secretary of Commerce and the U. S. Trade Representative within 90 days of the order. Probably the best outcome from this will be at least to lay to rest whether or not there are unfair trade practices going on.
The order to revise the succession in Justice is another routine adjustment. I have not delved into the details this time, but presume it is once again to line up the most sympathetic of U. S. Attorneys in case of recused officers or vacancies in the Justice department.
The order on antidumping and violations of trade and customs laws appears to be a kind of vetting of importers to be sure they are following laws. It requires bonding. I am no expert on this, so will not even attempt to comment further.
Following are the official titles: